Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New CAR-Treg therapy aims to tame autoimmune attacks

NCT ID NCT07502859

First seen Apr 01, 2026 · Last updated May 22, 2026 · Updated 11 times

Summary

This early-phase study tests the safety and effectiveness of an injection called BEN301 in 24 adults with autoimmune diseases like scleroderma, lupus, or myositis. The therapy uses specially engineered immune cells (CAR-Tregs) to calm the overactive immune system. The main goals are to check for side effects and see if it can reduce disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SSC RA SS IIM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boren Hospital, Beijing.

    Beijing, Beijing Municipality, 100070, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Jiaotong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.